Mergers & Acquisitions Mergers & Acquisitions

Illumina offers EU concessions over Grail deal as merger-review clock restarts

US biotech company Illumina has today offered to change the terms of its deal to acquire cancer-testing specialist Grail in a bid to assuage EU competition concerns over the transaction, according to an update to the EU regulator’s website this evening.

The review clock also officially restarted today, after the Europe

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Natalie McNelis

Senior Correspondent

Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Discover MLex

Stay on top of global regulatory developments

Latest News